{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:34:10Z","timestamp":1785411250435,"version":"3.56.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32DA035165"],"award-info":[{"award-number":["T32DA035165"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["L30DA056944"],"award-info":[{"award-number":["L30DA056944"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM140972"],"award-info":[{"award-number":["T32GM140972"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50DA054072"],"award-info":[{"award-number":["P50DA054072"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000058","name":"Substance Abuse and Mental Health Services Administration","doi-asserted-by":"publisher","award":["18-95529"],"award-info":[{"award-number":["18-95529"]}],"id":[{"id":"10.13039\/100000058","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The opioid epidemic has prompted nationwide efforts to expand access to medications for opioid use disorder (MOUD). Primary care settings have been identified as a critical access point for patients who may benefit from MOUD treatments. Despite implementation efforts, there is limited understanding of how MOUD practice capability in primary care settings evolves over time or what factors influence clinic-level implementation trajectories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a longitudinal study of 95 primary care clinics in California from 2019 to 2024. MOUD practice capability was measured using the Integrating Medications for Addiction Treatment in Primary Care (IMAT-PC) index across three timepoints. Using latent class growth analysis, we analyzed implementation growth trajectories and examined their associations with clinic characteristics and MOUD implementation outcomes (e.g., patient reach and provider adoption).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Three distinct implementation trajectory classes emerged: elevated improving (41.0%), moderate improving (47.4%), and low improving (11.6%). All clinics demonstrated improvements in MOUD practice capability over time. Elevated improving clinics primarily consisted of smaller clinics (&lt;\u200915,000 patients) and achieved significantly higher number of patients receiving MOUD compared to moderate (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03) and low improving clinics (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04). Clinics serving medically underserved populations disproportionately represented the low improving class (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Increase in the number of providers prescribing MOUD did not differ significantly across trajectory classes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although all clinics increased MOUD capability, we found significant associations between implementation trajectory classes and changes in patients receiving MOUD over time in primary care-based MOUD programs. Implementation supports may be more effective and efficient if selected and delivered based upon clinic contextual factors, particularly in resource-constrained and underserved settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-025-00600-y","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T23:02:09Z","timestamp":1756681329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Three trajectories of implementation of medications for opioid use disorder in primary care"],"prefix":"10.1186","volume":"20","author":[{"given":"Wayne","family":"Kepner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Vest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Risner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"McGovern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"600_CR1","doi-asserted-by":"crossref","unstructured":"Lyden J, Binswanger IA, editors. The united States opioid epidemic. Seminars in perinatology. Elsevier; 2019.","DOI":"10.1053\/j.semperi.2019.01.001"},{"key":"600_CR2","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s40615-017-0435-0","volume":"5","author":"DM Cole","year":"2018","unstructured":"Cole DM, Thomas DM, Field K, Wool A, Lipiner T, Massenberg N, et al. The 21st century cures act implications for the reduction of Racial health disparities in the US criminal justice system: a public health approach. J Racial Ethnic Health Disparities. 2018;5:885\u201393.","journal-title":"J Racial Ethnic Health Disparities"},{"key":"600_CR3","unstructured":"Murrin S. States\u2019 use of grant funding for a targeted response to the opioid crisis. US Department of Health and Human Services Office of Inspector General; 2020."},{"key":"600_CR4","unstructured":"Substance Abuse and Mental Health Services Administration. State Opioid Response Grants 2024 [cited 2024. Available from: https:\/\/www.samhsa.gov\/grants\/grant-announcements\/ti-24-008"},{"key":"600_CR5","unstructured":"21st Century Cures Act, 114th Congress Sess. (2016)."},{"key":"600_CR6","unstructured":"Stringfellow EJ, Humphreys K, Jalali MS. Removing the X-waiver is one small step toward increasing treatment of opioid use disorder, but great leaps are needed. Health Affairs Forefr. 2021."},{"key":"600_CR7","doi-asserted-by":"crossref","unstructured":"Witherell A. The federal response to the opioid epidemic: examining 2021 SAMHSA grant allocation. Columbia Univ J Global Health. 2022;12(2).","DOI":"10.52214\/cujgh.v12i2.9918"},{"key":"600_CR8","doi-asserted-by":"publisher","first-page":"209309","DOI":"10.1016\/j.josat.2024.209309","volume":"160","author":"MAG Estrada","year":"2024","unstructured":"Estrada MAG, Abraham AJ, Andrews CM, Grogan CM. Statewide efforts to address the opioid epidemic: results from a National survey of single state agencies. J Subst Use Addict Treat. 2024;160:209309.","journal-title":"J Subst Use Addict Treat"},{"key":"600_CR9","doi-asserted-by":"crossref","unstructured":"McNamara KF, Biondi BE, Hern\u00e1ndez-Ram\u00edrez RU, Taweh N, Grimshaw AA, Springer SA, editors. A systematic review and meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes. Open forum infectious diseases; 2021: Oxford University Press US.","DOI":"10.1093\/ofid\/ofab289"},{"issue":"4","key":"600_CR10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1176\/appi.ajp.2021.21070700","volume":"179","author":"BV Watts","year":"2022","unstructured":"Watts BV, Gottlieb DJ, Riblet NB, Gui J, Shiner B. Association of medication treatment for opioid use disorder with suicide mortality. Am J Psychiatry. 2022;179(4):298\u2013304.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"600_CR11","doi-asserted-by":"publisher","first-page":"e2327488","DOI":"10.1001\/jamanetworkopen.2023.27488","volume":"6","author":"CM Jones","year":"2023","unstructured":"Jones CM, Han B, Baldwin GT, Einstein EB, Compton WM. Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021. JAMA Netw Open. 2023;6(8):e2327488\u2013e.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"600_CR12","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1080\/00952990.2023.2251653","volume":"49","author":"RL Cooper","year":"2023","unstructured":"Cooper RL, Edgerton RD, Watson J, Conley N, Agee WA, Wilus DM, et al. Meta-analysis of primary care delivered buprenorphine treatment retention outcomes. Am J Drug Alcohol Abus. 2023;49(6):756\u201365.","journal-title":"Am J Drug Alcohol Abus"},{"issue":"6","key":"600_CR13","doi-asserted-by":"publisher","first-page":"e2419094","DOI":"10.1001\/jamanetworkopen.2024.19094","volume":"7","author":"B Del Pozo","year":"2024","unstructured":"Del Pozo B, Park JN, Taylor BG, Wakeman SE, Ducharme L, Pollack HA, et al. Knowledge, attitudes, and beliefs about opioid use disorder treatment in primary care. JAMA Netw Open. 2024;7(6):e2419094\u2013e.","journal-title":"JAMA Netw Open"},{"key":"600_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13722-021-00213-1","volume":"16","author":"EC Saunders","year":"2021","unstructured":"Saunders EC, Moore SK, Walsh O, Metcalf SA, Budney AJ, Cavazos-Rehg P, et al. It\u2019s way more than just writing a prescription: A qualitative study of preferences for integrated versus non-integrated treatment models among individuals with opioid use disorder. Addict Sci Clin Pract. 2021;16:1\u201316.","journal-title":"Addict Sci Clin Pract"},{"issue":"14","key":"600_CR15","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1080\/10826084.2021.1975749","volume":"56","author":"EF Madden","year":"2021","unstructured":"Madden EF, Prevedel S, Light T, Sulzer SH. Intervention stigma toward medications for opioid use disorder: A systematic review. Subst Use Misuse. 2021;56(14):2181\u2013201.","journal-title":"Subst Use Misuse"},{"key":"600_CR16","doi-asserted-by":"crossref","unstructured":"Buresh M, Stern R, Rastegar D. Treatment of opioid use disorder in primary care. BMJ. 2021;373.","DOI":"10.1136\/bmj.n784"},{"key":"600_CR17","doi-asserted-by":"publisher","first-page":"108083","DOI":"10.1016\/j.drugalcdep.2020.108083","volume":"213","author":"DR Roehler","year":"2020","unstructured":"Roehler DR, Guy GP Jr, Jones CM. Buprenorphine prescription dispensing rates and characteristics following federal changes in prescribing policy, 2017\u20132018: A cross-sectional study. Drug Alcohol Depend. 2020;213:108083.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"600_CR18","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1377\/hlthaff.2019.01622","volume":"39","author":"M Olfson","year":"2020","unstructured":"Olfson M, Zhang V, Schoenbaum M, King M. Buprenorphine treatment by primary care providers, psychiatrists, addiction specialists, and others: trends in buprenorphine treatment by prescriber specialty-primary care providers, psychiatrists, and addiction medicine specialists. Health Aff. 2020;39(6):984\u201392.","journal-title":"Health Aff"},{"key":"600_CR19","unstructured":"Office of Quality Improvement BoPHC. 2020 Uniform Data System Trends. 2020 Uniform Data System Trends [Internet]. 2021 march 5, 2025:[1\u201351 pp.]. Available from: https:\/\/data.hrsa.gov\/tools\/data-reporting"},{"issue":"Suppl 2","key":"600_CR20","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1370\/afm.2920","volume":"21","author":"H Klusaritz","year":"2023","unstructured":"Klusaritz H, Bilger A, Paterson E, Summers C, Barg FK, Cronholm PF, et al. Impact of stigma on clinician training for opioid use disorder care: a qualitative study in a primary care learning collaborative. Annals Family Med. 2023;21(Suppl 2):S31\u20138.","journal-title":"Annals Family Med"},{"key":"600_CR21","doi-asserted-by":"publisher","first-page":"263348952311528","DOI":"10.1177\/26334895231152808","volume":"4","author":"RM Cloutier","year":"2023","unstructured":"Cloutier RM, Cole ES, McDonough BL, Lomauro DA, Miller JP, Talbert AL, et al. Strategies to recruit rural primary care providers to implement a medication for opioid use disorder (MOUD) focused integrated care model. Implement Res Pract. 2023;4:26334895231152808.","journal-title":"Implement Res Pract"},{"issue":"5","key":"600_CR22","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1176\/appi.ps.202000565","volume":"73","author":"J McNeely","year":"2022","unstructured":"McNeely J, Schatz D, Olfson M, Appleton N, Williams AR. How physician workforce shortages are hampering the response to the opioid crisis. Psychiatric Serv. 2022;73(5):547\u201354.","journal-title":"Psychiatric Serv"},{"key":"600_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13012-017-0667-8","volume":"12","author":"F Hoekstra","year":"2017","unstructured":"Hoekstra F, van Offenbeek MA, Dekker R, Hettinga FJ, Hoekstra T, van der Woude LH, et al. Implementation fidelity trajectories of a health promotion program in multidisciplinary settings: managing tensions in rehabilitation care. Implement Sci. 2017;12:1\u201316.","journal-title":"Implement Sci"},{"key":"600_CR24","unstructured":"Center for Care Innovation. ATSH Primary Care Program Page 2021 [Available from: https:\/\/www.careinnovations.org\/atshprimarycare-teams\/"},{"key":"600_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1748-5908-8-139","volume":"8","author":"EK Proctor","year":"2013","unstructured":"Proctor EK, Powell BJ, McMillen JC. Implementation strategies: recommendations for specifying and reporting. Implement Sci. 2013;8:1\u201311.","journal-title":"Implement Sci"},{"key":"600_CR26","doi-asserted-by":"publisher","first-page":"108395","DOI":"10.1016\/j.jsat.2021.108395","volume":"126","author":"HC Garneau","year":"2021","unstructured":"Garneau HC, Hurley B, Fisher T, Newman S, Copeland M, Caton L, et al. The integrating medications for addiction treatment (IMAT) index: a measure of capability at the organizational level. J Subst Abuse Treat. 2021;126:108395.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"600_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13012-022-01239-y","volume":"17","author":"JH Ford","year":"2022","unstructured":"Ford JH, Cheng H, Gassman M, Fontaine H, Garneau HC, Keith R, et al. Stepped implementation-to-target: a study protocol of an adaptive trial to expand access to addiction medications. Implement Sci. 2022;17(1):64.","journal-title":"Implement Sci"},{"issue":"1","key":"600_CR28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s43058-022-00306-1","volume":"3","author":"H Cheng","year":"2022","unstructured":"Cheng H, McGovern MP, Garneau HC, Hurley B, Fisher T, Copeland M, et al. Expanding access to medications for opioid use disorder in primary care clinics: an evaluation of common implementation strategies and outcomes. Implement Sci Commun. 2022;3(1):72.","journal-title":"Implement Sci Commun"},{"key":"600_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10488-010-0319-7","volume":"38","author":"E Proctor","year":"2011","unstructured":"Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, et al. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Mental Health Mental Health Serv Res. 2011;38:65\u201376.","journal-title":"Adm Policy Mental Health Mental Health Serv Res"},{"key":"600_CR30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fpubh.2019.00064","volume":"7","author":"RE Glasgow","year":"2019","unstructured":"Glasgow RE, Harden SM, Gaglio B, Rabin B, Smith ML, Porter GC, et al. RE-AIM planning and evaluation framework: adapting to new science and practice with a 20-year review. Front Public Health. 2019;7:64.","journal-title":"Front Public Health"},{"issue":"3","key":"600_CR31","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/biomet\/88.3.767","volume":"88","author":"Y Lo","year":"2001","unstructured":"Lo Y, Mendell NR, Rubin DB. Testing the number of components in a normal mixture. Biometrika. 2001;88(3):767\u201378.","journal-title":"Biometrika"},{"key":"600_CR32","doi-asserted-by":"crossref","unstructured":"Nagin D. Group-based modeling of development. Harvard University Press; 2005.","DOI":"10.4159\/9780674041318"},{"issue":"1","key":"600_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1146\/annurev.clinpsy.121208.131413","volume":"6","author":"DS Nagin","year":"2010","unstructured":"Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Ann Rev Clin Psychol. 2010;6(1):109\u201338.","journal-title":"Ann Rev Clin Psychol"},{"key":"600_CR34","unstructured":"Muth\u00e9n B, Muth\u00e9n L, Mplus. Handbook of item response theory. Chapman and Hall\/CRC; 2017. pp. 507\u201318."},{"key":"600_CR35","unstructured":"R Core Team R. R: A language and environment for statistical computing. 2013."},{"issue":"7","key":"600_CR36","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.2105\/AJPH.2004.042432","volume":"95","author":"LG Hart","year":"2005","unstructured":"Hart LG, Larson EH, Lishner DM. Rural definitions for health policy and research. Am J Public Health. 2005;95(7):1149\u201355.","journal-title":"Am J Public Health"},{"issue":"2","key":"600_CR37","first-page":"147","volume":"12","author":"JC Kleinman","year":"1977","unstructured":"Kleinman JC, Wilson RW. Are medically underserved areas medically underserved? Health Serv Res. 1977;12(2):147.","journal-title":"Health Serv Res"},{"issue":"1","key":"600_CR38","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/08897077.2021.1931633","volume":"43","author":"JB Anderson","year":"2022","unstructured":"Anderson JB, Martin SA, Gadomski A, Krupa N, Mullin D, Cahill A, et al. Project ECHO and primary care buprenorphine treatment for opioid use disorder: implementation and clinical outcomes. Substance Abuse. 2022;43(1):222\u201330.","journal-title":"Substance Abuse"},{"issue":"2","key":"600_CR39","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1080\/08897077.2021.1891600","volume":"42","author":"P Nourjah","year":"2021","unstructured":"Nourjah P, Kato E. One size does not fit all and other lessons learned from grants for implementation of the AHRQ medication assisted treatment for opioid use disorder in rural primary care. Substance Abuse. 2021;42(2):136\u20139.","journal-title":"Substance Abuse"},{"issue":"1","key":"600_CR40","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1080\/08897077.2021.1932698","volume":"43","author":"CD Brackett","year":"2022","unstructured":"Brackett CD, Duncan M, Wagner JF, Fineberg L, Kraft S. Multidisciplinary treatment of opioid use disorder in primary care using the collaborative care model. Substance Abuse. 2022;43(1):240\u20134.","journal-title":"Substance Abuse"},{"key":"600_CR41","doi-asserted-by":"publisher","first-page":"263348952110058","DOI":"10.1177\/26334895211005809","volume":"2","author":"L Caton","year":"2021","unstructured":"Caton L, Shen H, Miele GM, Darfler K, Sandoval JR, Urada D, et al. Opening the black box: four common implementation strategies for expanding the use of medications for opioid use disorder in primary care. Implement Res Pract. 2021;2:26334895211005809.","journal-title":"Implement Res Pract"},{"key":"600_CR42","doi-asserted-by":"crossref","unstructured":"Kepner W, Meacham MC, Nobles AL. Types and sources of stigma on opioid use treatment and recovery communities on Reddit. Subst Use Misuse. 2022:1\u201312.","DOI":"10.1080\/10826084.2022.2091786"},{"issue":"1suppl","key":"600_CR43","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1177\/00333549231170216","volume":"138","author":"GS Leibowitz","year":"2023","unstructured":"Leibowitz GS, Turner W, Bruckenthal P, Mezzatesta M, Ramsey KS, Dyer ME. Lessening the impact of opioid misuse at a federally qualified health center in new york: outcomes of an integrated workforce training program. Public Health Rep. 2023;138(1suppl):S42\u20137.","journal-title":"Public Health Rep"},{"issue":"12","key":"600_CR44","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1001\/jamainternmed.2023.5701","volume":"183","author":"PD Wartko","year":"2023","unstructured":"Wartko PD, Bobb JF, Boudreau DM, Matthews AG, McCormack J, Lee AK, et al. Nurse care management for opioid use disorder treatment: the PROUD cluster randomized clinical trial. JAMA Intern Med. 2023;183(12):1343\u201354.","journal-title":"JAMA Intern Med"},{"key":"600_CR45","doi-asserted-by":"publisher","first-page":"108783","DOI":"10.1016\/j.drugalcdep.2021.108783","volume":"225","author":"CM Jones","year":"2021","unstructured":"Jones CM, Diallo MM, Vythilingam M, Schier JG, Eisenstat M, Compton WM. Characteristics and correlates of US clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic. Drug Alcohol Depend. 2021;225:108783.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"600_CR46","doi-asserted-by":"publisher","first-page":"qxad013","DOI":"10.1093\/haschl\/qxad013","volume":"1","author":"N Krawczyk","year":"2023","unstructured":"Krawczyk N, Rivera BD, King C, Dooling BC. Pandemic telehealth flexibilities for buprenorphine treatment: a synthesis of evidence and policy implications for expanding opioid use disorder care in the united States. Health Affairs Scholar. 2023;1(1):qxad013.","journal-title":"Health Affairs Scholar"},{"issue":"Supplement","key":"600_CR47","doi-asserted-by":"publisher","first-page":"S136","DOI":"10.3122\/jabfm.2021.S1.200207","volume":"34","author":"DT O\u2019Gurek","year":"2021","unstructured":"O\u2019Gurek DT. Designing and evaluating COVID-19 protocols for an office-based opioid treatment program in an urban underserved setting. J Am Board Family Med. 2021;34(Supplement):S136\u201340.","journal-title":"J Am Board Family Med"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00600-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00600-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00600-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:52:48Z","timestamp":1781610768000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13722-025-00600-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["600"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00600-y","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Individual patient data were reported in aggregate form only, and no individually identifiable patient information was collected.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}